Large gap with delayed quotes
Analysis date: 27.06.2025
Global Evaluation
Slightly positive
Slightly positive
The stock is classified in the slightly positive zone since 24.06.2025.
Interest
Weak
Weak
Two stars since 27.06.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 27.06.2025 at a price of 255.16.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately overvalued.
MT Tech Trend
Positive
Positive
The forty day technical trend is positive since 25.04.2025.
4wk Rel Perf
-0.62%
-0.62%
The four-week dividend-adjusted performance versus SP500 is .
Sensibility
Low
Low
The stock has been on the low-sensitivity level since 24.06.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.15%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.38%.
Mkt Cap in $bn
37.41
37.41
With a market capitalization >$8bn, RESMED is considered a large-cap stock.
G/PE Ratio
0.79
0.79
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
21.90
21.90
The estimated PE is for the year 2027.
LT Growth
16.37%
16.37%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
23
23
Over the last seven weeks, an average of 23 analysts provided earnings per share estimates.
Dividend Yield
0.93%
0.93%
The twelve month estimated dividend yield represents 20.25% of earnings forecasts.
Beta
67
67
For 1% of index variation, the stock varies on average by 0.67%.
Correlation
0.46
0.46
46.05% of stock movements are explained by index variations.
Value at Risk
27.84
27.84
The value at risk is estimated at USD 27.84. The risk is therefore 10.91%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.01.2002
02.01.2002